Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
From Strategy and Development to Infusion and Safety Follow-up
For decades, UBC has served as a trusted partner to bringing first in class, new molecular entities to market. We understand the challenges that our biopharmaceutical partners are facing when considering their clinical development, post-approval, and commercial evidence generation strategies.
We are a multidisciplinary team of epidemiologists, clinical development experts, safety and risk management experts who harness strong experience across the development lifecycle for cellular and gene therapies. We are passionate caregivers and educators that support and guide our clients and their patients to obtain access to these life changing therapies.
Relapsed or refractory large B-cell lymphoma • Relapsed/refractory mantle cell lymphoma (r/r MCL) • B-cell precursor acute lymphoblastic leukemia (ALL)
Spinal Muscular Atrophy • Hemophilia A • Hemophilia B • BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC)